Notice of Intent: Measuring AAV9 vector DNA in mice tissue using qPCR

The National Institutes of Health, specifically the National Human Genome Research Institute DIR Molecular Genetics Section, intends to award a Firm-Fixed-Price Purchase Order to Charles River Laboratories Montreal ULC under solicitation 75N98027Q00015. This procurement is designed to support an FDA Investigational New Drug application by testing the efficacy and non-toxicity of therapeutic adenine DNA base editing administered via Adeno-Associated Virus 9 in a humanized mouse model of Hutchinson Gilford Progeria Syndrome. The scope of work includes mouse tissue histology processing, histopathology staining, and AAV9 antibody screening of mouse serum samples to demonstrate non-toxicity six months post-treatment, all of which must be supported by GLP-compliant documentation. This is a non-competitive presolicitation notice with a response deadline of October 21, 2026. While the intent is to award to a specific vendor, small businesses are permitted to submit written capability statements to the primary point of contact, David Shen, to demonstrate their ability to perform the requirements. The performance of these services is associated with the NIH office located in Bethesda, Maryland, under NAICS code 541380.